David Hoffmann - Durect Lead Independent Director
| DRRX Stock | USD 0.88 0.10 12.82% |
Director
Mr. David R. Hoffmann is an Chairman of the Board of the Company effective December 31, 2018. Mr. Hoffmann served as a Director of DURECT since December 2002 and as Lead Independent Director since December 2010. He had a distinguished career at ALZA Corporation from 1976 to 2002, where he held roles of increasing responsibility, including serving as Vice President and Treasurer for 10 years until his retirement inOctober 2002 since 2018.
| Age | 69 |
| Tenure | 6 years |
| Address | 10260 Bubb Road, Cupertino, CA, United States, 95014-4166 |
| Phone | 408 777 1417 |
| Web | https://www.durect.com |
Durect Management Efficiency
The company has return on total asset (ROA) of (0.4379) % which means that it has lost $0.4379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3893) %, meaning that it created substantial loss on money invested by shareholders. Durect's management efficiency ratios could be used to measure how well Durect manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.74 in 2024. Return On Capital Employed is likely to rise to -1.93 in 2024. At this time, Durect's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 121.6 K in 2024.Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Robert Nostrand | Intracellular Th | 61 | |
| Rory Riggs | Intracellular Th | 65 | |
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
| Thomas Penn | ANI Pharmaceuticals | 72 | |
| Peter Lankau | ANI Pharmaceuticals | 60 | |
| Michael Rawlins | Intracellular Th | 72 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
| Joel Marcus | Intracellular Th | 70 | |
| Richard Lerner | Intracellular Th | 79 | |
| David Nash | ANI Pharmaceuticals | 62 | |
| Fred Holubow | ANI Pharmaceuticals | 77 | |
| Patrick Walsh | ANI Pharmaceuticals | 57 | |
| Christopher Alafi | Intracellular Th | 54 | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.44 |
Durect Leadership Team
Elected by the shareholders, the Durect's board of directors comprises two types of representatives: Durect inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Durect. The board's role is to monitor Durect's management team and ensure that shareholders' interests are well served. Durect's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Durect's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon Benito, Independent Director | ||
| Gail Farfel, Director | ||
| James DVM, CEO, CoFounder | ||
| Norman MD, Chief Officer | ||
| Keith MBA, Commercial Development | ||
| David Hoffmann, Lead Independent Director | ||
| Terrence Blaschke, Independent Director | ||
| Timothy MBA, CFO Secretary | ||
| WeiQi MD, Executive Scientist | ||
| Judy Joice, Sr. VP of Operations and Corporate Quality Assurance | ||
| Michael Arenberg, CFO | ||
| Jian MBA, Corporate Finance | ||
| Su Yum, Executive Officer | ||
| James Brown, President CEO, Director | ||
| Armand Neukermans, Independent Director | ||
| Felix Theeuwes, Chairman of the Board, Chief Scientific Officer | ||
| Andrew Miksztal, VP Scientist | ||
| Judith Robertson, Director | ||
| Jon Saxe, Independent Director | ||
| Jay Shepard, Director | ||
| Myriam Theeuwes, Senior Vice President - Clinical Development | ||
| Matthew Hogan, CFO | ||
| Steve JD, VP Counsel |
Durect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Durect a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (2.34) % | ||||
| Current Valuation | 15.76 M | ||||
| Shares Outstanding | 31.04 M | ||||
| Shares Owned By Insiders | 5.97 % | ||||
| Shares Owned By Institutions | 22.55 % | ||||
| Number Of Shares Shorted | 1.03 M | ||||
| Price To Earning | (3.09) X | ||||
| Price To Book | 1.62 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Durect in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Durect's short interest history, or implied volatility extrapolated from Durect options trading.
Pair Trading with Durect
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Durect position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Durect will appreciate offsetting losses from the drop in the long position's value.Moving together with Durect Stock
| 0.71 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.74 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Durect Stock
| 0.61 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.58 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.57 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.56 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.55 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Durect could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Durect when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Durect - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Durect to buy it.
The correlation of Durect is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Durect moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Durect moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Durect can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Durect. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Durect Stock please use our How to Invest in Durect guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Durect Stock analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Durect's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Durect. If investors know Durect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Durect listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.326 | Quarterly Revenue Growth (0.20) | Return On Assets (0.44) | Return On Equity (1.39) |
The market value of Durect is measured differently than its book value, which is the value of Durect that is recorded on the company's balance sheet. Investors also form their own opinion of Durect's value that differs from its market value or its book value, called intrinsic value, which is Durect's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Durect's market value can be influenced by many factors that don't directly affect Durect's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Durect's value and its price as these two are different measures arrived at by different means. Investors typically determine if Durect is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Durect's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.